Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Acxiom Corporation (ACXM): Ken Griffin Boosts His Stake Betting on Company Turning Around

In a new filing with the US Securities and Exchange Commission, Ken Griffin‘s Citadel Investment Group reported a significant position in Acxiom Corporation (NASDAQ:ACXM). Mr. Griffin has boosted his fund’s stake to over 4.0 million shares, from around 1.29 million held at the end of June, as reported in the latest 13F filing. Following the increase, Citadel’s passive stake amasses 5.2% of Acxiom’s common stock.


Acxiom Corporation (NASDAQ:ACXM). is a $1.30 billion technology company which provides enterprise data and analytics services. The stock of the company dropped by more than 54% since the beginning of the year amid the company delivering weak financial results, which however does not seem to stop Ken Griffin, who acquired more shares since the beginning of the year. As previous 13F filings with the SEC show, Citadel initiated a stake in Acxiom during the first quarter and held 69,200 shares at the end of March, the stake being later boosted to 1.29 million shares.

Even though Acxiom Corporation (NASDAQ:ACXM) has reported a decline in its revenue and net income, it has justified the drop by restructuring and transformation activities, which could mean that the market overreacted on the news, leading to a decline of the stock. For the second quarter of the year (the first of the fiscal year), the revenue of the company declined to $242 million from $266 million a year ago, while the EPS fell to a loss of $0.08 from an income of $0.17 in the same period of last year. As it was mentioned in a statement, the main reason for the income’s decline is the company’s recent acquisition of LiveRamp, a service that onboard customer data into digital marketing applications. Under its restructuring plan, Acxiom Corporation (NASDAQ:ACXM). sold its UK-based call center business, 2Touch, which also affected the company’s revenues.

Overall, for the fiscal year 2015, Acxiom Corporation (NASDAQ:ACXM). still expects that its revenue from continuing operations will decline by around 5%, mainly because of a loss of IT Infrastructure Management customers and the exit of the company’s analog paper survey business in Europe. The company expects its EPS between $0.73 and $0.83 for the current fiscal year.

In addition, Mr. Griffin is not the only investor betting on the company finishing its restructuring and turning back to profit. Among the funds that we track at Insider Monkey, several have boosted their positions in Acxiom Corporation (NASDAQ:ACXM)., as the latest round of 13F filings shows. Mariko Gordon‘s Daruma Asset Management increased its position by 18% on the quarter to 3.12 million shares, while Joel Greenblatt‘s Gotham Asset Management and Jim Simons‘ Renaissance Technologies surged their stakes by 930% and 109% respectively to 1.12 million and 1.04 million shares respectively. However, we should mention that the stakes account for very small portions of the funds’ equity portfolios.

Disclosure: none

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!